The role of anthracyclines in epithelial ovarian cancer

Cyclophosphamide and Cisplatin Compared with Paclitaxel and Cisplatin in Patients with Stage III and Stage IV Ovarian Cancer

1996 • 2,766 citations

Reduction of Doxorubicin Cardiotoxicity by Prolonged Continuous Intravenous Infusion

1982 • 768 citations

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1997 • 648 citations

Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer.

1997 • 628 citations

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

1995 • 476 citations

Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin

1997 • 468 citations

Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.

1989 • 328 citations

ICRF-187 permits longer treatment with doxorubicin in women with breast cancer.

1992 • 328 citations

Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma.

1987 • 307 citations

Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Advanced Ovarian Cancer Trialists Group.

1991 • 291 citations

Chemotherapy in advanced ovarian cancer: An overview of randomised clinical trials

1991 • 272 citations

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy.

1997 • 271 citations

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients

1997 • 267 citations

RANDOMISED TRIAL COMPARING TWO COMBINATION CHEMOTHERAPY REGIMENS (HEXA-CAF VS CHAP-5) IN ADVANCED OVARIAN CARCINOMA

1984 • 246 citations

Reduced Cardiotoxicity of Doxorubicin Delivered on a Weekly Schedule

1983 • 220 citations

Anthracycline Antibiotics in Cancer Therapy

1994 • 211 citations

Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity and toxicity

1993 • 196 citations

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis. The Ovarian Cancer Meta-Analysis Project.

1991 • 186 citations

Experimental model systems of ovarian cancer: applications to the design and evaluation of new treatment approaches.

1984 • 162 citations

Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

1992 • 161 citations

Drugs ten years later: Epirubicin

1993 • 160 citations

A randomized trial comparing cisplatin plus cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide in advanced ovarian cancer.

1986 • 160 citations

Multicenter randomized controlled clinical trial to evaluate cardioprotection of dexrazoxane versus no cardioprotection in women receiving epirubicin chemotherapy for advanced breast cancer.

1996 • 158 citations

Pharmacological-toxicological expert report. CAELYX. (Stealth liposomal doxorubicin HCl).

1996 • 152 citations

Impact of doxorubicin on survival in advanced ovarian cancer.

1995 • 149 citations

Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas.

1998 • 137 citations

A randomized study of cyclophosphamide and cis-platinum with or without doxorubicin in advanced ovarian carcinoma

1987 • 112 citations

Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes

1993 • 98 citations

Second trial drugs in ovarian cancer

1977 • 88 citations

Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites.

1980 • 88 citations

Cloning of human ovarian cancer cells in soft agar from malignant and peritoneal washings.

1980 • 73 citations

Cyclophosphamide plus cisplatin versus cyclophosphamide, doxorubicin, and cisplatin chemotherapy of ovarian carcinoma: a meta-analysis

1998 • 69 citations

Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.

1986 • 62 citations

Carboplatin, doxorubicin, and cyclophosphamide versus cisplatin, doxorubicin, and cyclophosphamide: a randomized trial in stage III-IV epithelial ovarian carcinoma.

1991 • 59 citations

Idarubicin: an anthracycline antineoplastic agent.

1992 • 47 citations

Melphalan versus adriamycin in the treatment of advanced carcinoma of the ovary.

1975 • 44 citations

Meta-analysis of the role of platinum compounds in advanced ovarian carcinoma. The Advanced Ovarian Cancer Trialists Group.

1992 • 43 citations

Adriamycin therapy for advanced ovarian carcinoma recurrent after chemotherapy.

1978 • 39 citations

Cisplatin regimens and improved prognosis of patients with poorly differentiated ovarian cancer

1983 • 38 citations

Multilevel therapeutic targeting by topoisomerase inhibitors.

1994 • 34 citations

Randomised trial comparing combinations of cyclophosphamide and cisplatin without or with doxorubicin or 4′‐epi‐doxorubicin in the treatment of advanced ovarian cancer

1988 • 29 citations

Meta-analysis of chemotherapy regimens for ovarian carcinoma: a reassessment of cisplatin, cyclophosphamide and doxorubicin versus cisplatin and cyclophosphamide.

1997 • 28 citations

Randomized Comparison of Cisplatin plus Epirubicin or Doxorubicin for Advanced Epithelial Ovarian Carcinoma

1992 • 25 citations

High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience.

1995 • 24 citations

Adriamycin in ovarian cancer patients resistant to cyclophosphamide

1978 • 22 citations

Adriamycin versus adriamycin plus melphalan in advanced ovarian carcinoma.

1977 • 22 citations

The Role of Hexamethylmelamine in the Combination Chemotherapy of Advanced Ovarian Cancer

1990 • 18 citations

Treatment of advanced ovarian cancer: A randomised trial comparing adriamycin or 4′epi‐adriamycin in combination with cisplatin and cyclophosphamide

1986 • 17 citations

A Phase 2 Study with Epirubicin as Second-Line Treatment of Patients with Advanced Epithelial Ovarian Cancer

1996 • 15 citations

Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5

1984 • 14 citations

Single-agent adriamycin followed by combination hexamethylmelamine-cyclophosphamide for advanced ovarian carcinoma

1982 • 14 citations

Developing new drugs for ovarian cancer: A challenging task in a changing reality

1984 • 12 citations

Sequential cisplatin-doxorubicin, early debulking surgery and intraperitoneal chemotherapy in advanced ovarian cancer

1992 • 7 citations

Cyclophosphamide, epirubicin and cisplatin (CEP) versus epirubicin plus cisplatin (EP) in stage Ic-IV ovarian cancer: a randomized phase III trial of the Gynecologic Oncology Group of the Comprehensive Cancer Center Limburg

1999 • 7 citations

Activity of Epirubicin in Combination Chemotherapy of Advanced Ovarian Cancer

1987 • 7 citations

Chemotherapy Consisting of Cisplatin, Epirubicin, and Cyclophosphamide in Advanced Ovarian Carcinoma

1993 • 5 citations

4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.

1984 • 3 citations